1Department of Pediatric Hematology and Oncology, Assistance Publique-Hôpitaux de Paris, GH HUEP, Armand Trousseau Hospital, Paris, France; Sorbonne Université, UMRS_938, Paris, France
2Department of Pediatric Hematology and Oncology, Children's Hospital, Bordeaux University, Bordeaux, France
3Department of Pediatric Hematology and Immunology, Robert Debré Hospital, AP-HP and University Paris Diderot, Paris, France
4Department of Pediatric Hematology, Children's Hospital and CRCT-Oncopole, Toulouse, France
5Department of Clinical Pharmacology and Unité de Recherche Clinique, AP-HP, Hôpital Saint Antoine, Paris, France; Sorbonne Université, Paris, France
6Department of Pediatric Hematology-Oncology, Jeanne de Flandre Hospital, CHRU and Lille 2 University, Lille, France
7Department of Immuno-Hemato-Pediatrics, Hospices Civils de Lyon, Claude Bernard University, Lyons, France
8Department of Pediatric Hematology and Oncology and Research Unit EA 3279, Aix-Marseille University and Timone Hospital, Marseilles, France
9Department of Pediatric Hematology and Oncology, University Hospital of Rennes, Rennes, France
10Department of Cytogenetics, Saint-Louis Hospital, AP-HP, Paris, France
11Laboratory of Hematology, Robert Debré Hospital, AP-HP, Paris, France; University Paris Diderot, Paris, France
12Laboratory of Hematology, Armand Trousseau Hospital, AP-HP and Sorbonne Université, UMRS_938, Paris, France.
Correspondence: Arnaud Petit (e-mail: email@example.com).
Citation: Petit A, Ducassou S, Leblanc T, Pasquet M, Rousseau A, Ragu C, Cachanado M, Nelken B, Bertrand Y, Michel G, Gandemer V, Cuccuini W, Fenneteau O, Lapillonne H, Auvrignon A, Baruchel A, Leverger G, on behalf of SFCE. Maintenance Therapy With Interleukin-2 for Childhood AML: Results of ELAM02 Phase III Randomized Trial. HemaSphere, 2018;2:1. http://dx.doi.org/10.1097/HS9.0000000000000159
Funding/support: This study was supported by a grant from the French Ministry of Health (PHRC-K 2003 no. 03142). Novartis provided the PROLEUKIN. The sponsor was Assistance Publique-Hôpitaux de Paris (Département de la Recherche Clinique et du Développement, Clinical Research and Development Department). CONECT-AML (COllaborative Network for Children and Teenagers with Acute Myeloblastic Leukemia) is supported by a grant from InCA, Fondation ARC, Ligue nationale contre le cancer, and Association Laurette Fugain (InCa-ARC-LIGUE_11905). Supported by PHRC National 2003, ELAM02 protocol N/REF: AOM03142, P030441.
Disclosure: The authors have indicated they have no potential conflicts of interest to disclose.
Clinical trial information: NCT00149162.
Author contributions: AA, AB, VG, TL, GL, GM, BN, and YB conceived the study; MC and AR performed statistical analysis; AA, MC, GL, AP, AR, and CR analyzed and interpreted data; AP, GL, and CR wrote the manuscript; all authors approved the manuscript. This article was written on behalf of the 28 participating centers of the SFCE and the investigators: Nathalie Aladjidi, Corinne Armari, Claire Berger, Laurence Blanc, Pascale Blouin, Benoit Brethon, Hervé Chambost, Gérard Couillault, Jean-Hugues Dalle, Anne Deville, Catherine Devoldere, Catherine Dollfus, Jean Donadieu, Cécile Dumesnil De Maricourt, Natacha Entz-Werle, Sylvie Fasola, Fanny Fouyssac, Claire Galambrun, Stéphanie Gorde-Grosjean, Stéphanie Haouy, Mathilde Jehanne, Charlotte Jubert, Justina Kanold, Anne Lambilliotte, Anne Lutun, Judith Landman-Parker, Odile Lejars, Patrice Lutz, Aude Marie-Cardine, Françoise Mazingue, Odile Minckes, Frédéric Millot, Claire Oudin, Caroline Oudot, Catherine Paillard, Isabelle Pellier, Yves Perel, Dominique Plantaz, Geneviève Plat, Maryline Poiree, Fanny Rialland, Yves Reguerre, Pierre Rohrlich, Claudine Schmitt, Pascale Schneider, Nicolas Sirvent, Jean-Louis Stephan, Marie-Dominique Tabone, Caroline Thomas, Jean-Pierre Vannier, Karima Yacouben.
Supplemental Digital Content is available for this article.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.hemaspherejournal.com).
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
Received September 4, 2018
Accepted October 11, 2018